Doxapram hydrochloride hydrate
Based on 1 Customer Validation
Doxapram hydrochloride hydrate is a respiratory stimulant. Doxapram hydrochloride hydrate increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram hydrochloride hydrate inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram hydrochloride hydrate significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram hydrochloride hydrate can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity.
For research use only. We do not sell to patients.
- Purity: 99.28%
- CAS No.: 7081-53-0
- Formula: C24H33ClN2O3
- Molecular Weight:432.98
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Pediatric Drug Library
HY-L104
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Potassium Channel Compound Library
HY-L119
-
Human Metabolite Library
HY-L123
-
Osteogenesis Compound Library
HY-L131
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
Biological Activity
Doxapram hydrochloride hydrate (0.01-100 μM, 10-30 min) inhibits human and porcine TASK-1 with IC50s of 0.88 and 0.93 μM in human and porcine atrial muscle cells[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Doxapram hydrochloride hydrate (> 1 mg/kg, i.v.) stimulates the brainstem respiratory center rather than the peripheral chemoreceptors in dogs[4].
Doxapram hydrochloride hydrate (1-2 mg/kg, i.v., single dose or once daily for 14 days) has a specific anti-arrhythmic effect on the atrium in domestic pigs[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acute atrial fibrillation and persistent atrial fibrillation models established in domestic pigs[6]
-
Dosage:1 and 2 mg/kg (single dose) and 2 mg/kg (continuous administration)
-
Administration:Intravenous injection (i.v.), single dose or once daily for 14 days
-
Result:Prolonged the effective refractory period of the atrium (AERP), but has no effect on ventricular repolarization.
Reversed the electrical remodeling associated with AF (increased TASK-1 current and shortened APD) in long-term treatment.
Chemical Information
-
CAS No. 7081-53-0
-
Appearance Solid
-
Molecular Weight 432.98
-
Formula C24H33ClN2O3
-
Color White to off-white
-
SMILES
O=C1N(CC)CC(CCN2CCOCC2)C1(C3=CC=CC=C3)C4=CC=CC=C4.Cl.O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 50 mg/mL (115.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (57.74 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cotten JF, et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg, 2006, 102(3), 779-785. [Content Brief]
[2]. Anderson-Beck, R., et al., Doxapram stimulates dopamine release from the intact rat carotid body in vitro. Neurosci Lett, 1995. 187(1): p. 25-8. [Content Brief]
[3]. Peers, C., Effects of doxapram on ionic currents recorded in isolated type I cells of the neonatal rat carotid body. Brain Res, 1991. 568(1-2): p. 116-22. [Content Brief]
[4]. Yost CS. A new look at the respiratory stimulant doxapram. CNS Drug Rev. 2006 Fall-Winter;12(3-4):236-49. [Content Brief]
[5]. Vliegenthart RJ, et al. Doxapram Treatment for Apnea of Prematurity: A Systematic Review. Neonatology. 2017;111(2):162-171. doi: 10.1159/000448941. Epub 2016 Oct 20. [Content Brief]
[6]. Wiedmann F, et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res. 2022 Jun 22;118(7):1728-1741. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.3096 mL | 11.5479 mL | 23.0958 mL | 57.7394 mL |
| 5 mM | 0.4619 mL | 2.3096 mL | 4.6192 mL | 11.5479 mL | |
| 10 mM | 0.2310 mL | 1.1548 mL | 2.3096 mL | 5.7739 mL | |
| 15 mM | 0.1540 mL | 0.7699 mL | 1.5397 mL | 3.8493 mL | |
| 20 mM | 0.1155 mL | 0.5774 mL | 1.1548 mL | 2.8870 mL | |
| 25 mM | 0.0924 mL | 0.4619 mL | 0.9238 mL | 2.3096 mL | |
| 30 mM | 0.0770 mL | 0.3849 mL | 0.7699 mL | 1.9246 mL | |
| 40 mM | 0.0577 mL | 0.2887 mL | 0.5774 mL | 1.4435 mL | |
| 50 mM | 0.0462 mL | 0.2310 mL | 0.4619 mL | 1.1548 mL | |
| DMSO | 60 mM | 0.0385 mL | 0.1925 mL | 0.3849 mL | 0.9623 mL |
| 80 mM | 0.0289 mL | 0.1443 mL | 0.2887 mL | 0.7217 mL | |
| 100 mM | 0.0231 mL | 0.1155 mL | 0.2310 mL | 0.5774 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Doxapram hydrochloride hydrate Related Classifications
HY-B0551A Related Classifications
Powered by Bioz